Characteristics, management and prognosis of elderly patients in the Euro Heart Survey on atrial fibrillation

Aging Clinical and Experimental Research

Volumn 24, Issue 5, 2012, Pages 517-523

  Fumagalli, Stefano ^a   Nieuwlaat, Robby ^b   Tarantini, Francesca ^a   De Vos, Cees B ^b   Werter, Christ J ^c   Le Heuzey, Jean Yves ^d   Marchionni, Niccolò ^a   Crijns, Harry J G M ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LAURENTIUS HOSPITAL   (Netherlands)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Atrial fibrillation; Elderly; Guidelines; Management; Oral anticoagulation; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SOTALOL; VERAPAMIL;

ADULT; AGED; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR MORTALITY; CARDIOVERSION; CATHETER ABLATION; CLINICAL FEATURE; DIAGNOSTIC TEST; DRUG INDICATION; FEMALE; FOLLOW UP; GERIATRIC CARE; GERIATRIC PATIENT; GROUPS BY AGE; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTED HEART PACEMAKER; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PATIENT REFERRAL; PRACTICE GUIDELINE; PROGNOSIS; REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CARDIOLOGY; EUROPE; FEMALE; HEART DISEASES; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; STROKE;

EID: 84874643292     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.3275/8408     Document Type: Review

References (30)

1. Fang MC, Chen J, Rich MW. Atrial fibrillation in the elderly. Am J Med 2007; 120: 481-7.
2. Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53.
3. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006; 9: 348-56.
4. Dorian P, Jung W, Newman D et al. The impairment of healthrelated quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 2000; 36: 1303-9.
5. Miyasaka Y, Barnes ME, Bailey KR et al. Mortality trends in patients diagnosed with first atrial fibrillation - a 21-year communitybased study. J Am Coll Cardiol 2007; 49: 986-92.
6. Fumagalli S, Tarantini F, Guarducci L et al. Atrial fibrillation is a possible marker of frailty in hospitalized patients: results of the GIFA Study. Aging Clin Exp Res 2010; 22: 129-33.
7. Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107: 2920-5.
8. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary - A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001; 104: 2118-50.
9. Miyasaka Y, Barnes ME, Petersen RC et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J 2007; 28: 1962-7.
10. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-96.
11. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007; 297: 1233-40.
12. Nieuwlaat R, Capucci A, Camm AJ et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-34.
13. Nieuwlaat R, Prins MH, Le Heuzey JY et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008; 29: 1181-9.
14. Eurostat - Statistical Office of the European Communities. Available at: http://epp.eurostat.ec.europa.eu/portal/page/portal/population/data/database. Accessed: July 2011.
15. Bilato C, Corti MC, Baggio G et al. Prevalence, functional impact, and mortality of atrial fibrillation in an older Italian population (from the Pro.V.A. study). Am J Cardiol 2009; 104: 1092-7.
16. Wann LS, Curtis AB, January CT et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57: 223-42.
17. Komajda M, Hanon O, Hochadel M et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 2009; 30: 478-86.
18. Nieuwlaat R, Capucci A, Lip GY et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-26.
19. Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
20. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation 2011; 124: 824-9.
21. Singer DE, Chang Y, Fang MC et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
22. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
23. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace 2011; 13: 329-45.
24. Lafuente-Lafuente C, Emery C, Laurendeau C, Fagnani F, Bergmann JF. Long term treatment of atrial fibrillation in elderly patients: A decision analysis. Int J Cardiol 2012; 155: 102-9.
25. Fumagalli S, Boncinelli L, Bondi E et al. Does advanced age affect the immediate and long-term results of direct-current external cardioversion of atrial fibrillation? J Am Geriatr Soc 2002; 50: 1192-7.
26. Zado E, Callans DJ, Riley M et al. Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in the elderly. J Cardiovasc Electrophysiol 2008; 19: 621-6.
27. Camm AJ, Capucci A, Hohnloser SH et al. A randomized activecontrolled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011; 57: 313-21.
28. Olshansky B, Rosenfeld LE, Warner AL et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004; 43: 1201-8.
29. Marcus GM, Alonso A, Peralta CA et al. European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation 2010; 122: 2009-15.
30. Parmley WW. Do we practice geriatric cardiology? J Am Coll Cardiol 1997; 29: 217-8.